Federico Rodriguez-Porcel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Federico Rodriguez-Porcel has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
Alberto J. Espay
James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA
5 shared publications- Anne-Marie Wills
Department of Neurology, Mass General Brigham, Boston, MA
4 shared publications - Joseph P. M. Kane
Centre for Public Health, Queen’s University Belfast, Belfast, UK
4 shared publications - Alberto J. Espay
James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA
3 shared publications - Alexander Pantelyat
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
3 shared publications Alok K. Dwivedi
From the Neurology Unit (A. Pilotto, A.S., B.B., A.L., A. Padovani), Department of Clinical and Experimental Sciences, and Neuroradiology Unit (R.G.), Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia; Parkinson's Disease Rehabilitation Centre (A. Pilotto, M.C.R.), FERB ONLUS–S. Isidoro Hospital, Trescore Balneario, Bergamo; Department of Neuroscience “Rita Levi Montalcini” (A.R., E.M., L.L.) and Autonomic Unit (S.M.), Department of...
3 shared publications
Latest Publications
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10)
Proximity to Water Pollutant Facilities and Risk of Incident Progressive Supranuclear Palsy
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10)
Proximity to Water Pollutant Facilities and Risk of Incident Progressive Supranuclear Palsy
- Open Access
- 5 November 2026
- Published by Springer Nature in Alzheimer's Research & Therapy
Initial development of the lewy body dementia – domain rating scale: a disease-specific outcome measure
- 5 November 2026
- Published by Springer Nature in Alzheimer's Research & Therapy
Open AccessInitial development of the lewy body dementia – domain rating scale: a disease-specific outcome measure
- Open Access
- 26 August 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (11) , 2689-2707
Breathe, Eat, Talk: Three Essential Ingredients to Quality‐of‐Life Outcomes in Movement Disorders
Background: Breathing, eating, and talking (BET) impairments are common yet frequently underrecognized features of movement disorders. Deficits in respiration, swallowing, voice, and speech may emerge early in the course of a disease, adversely affecting safety, participation, and quality of life. Routine neurological examinations may not adequately capture their impact. Objective: To characterize the clinical importance of BET dysfunction across several movement disorders by comparing neurological and speech‐language pathology (SLP) approaches to assessment and recommendations for improved early identification, referral and multidisciplinary management. Methods: Case examples were used to illustrate and compare clinical findings obtained through standard neurological evaluation versus comprehensive SLP assessment. A targeted literature review and comparison of commonly used neurology and SLP clinical tools were also conducted to examine current approaches to BET evaluation and referral. Results: Case examples illustrated how routine neurological examinations underestimated the severity and functional impact of BET impairments. This was contrasted with SLP identification of clinically meaningful deficits in respiratory function, cough, swallowing safety, communication effectiveness, and quality of life not captured by standard disease rating scales. Review of the literature demonstrated that commonly used neurological rating scales provide limited evaluation of BET dysfunction, whereas multidisciplinary assessment incorporating caregiver input, patient‐reported outcomes, perceptual evaluation, and instrumental testing improves detection and treatment planning. Conclusion: BET dysfunction is prevalent across movement disorders and substantially influences quality of life. Early referral to SLPs and integration of multidisciplinary BET assessment can improve diagnostic precision, facilitate timely intervention, reduce preventable complications, and support person‐centered care throughout disease progression.
- 26 August 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (11) , 2689-2707
Open AccessBreathe, Eat, Talk: Three Essential Ingredients to Quality‐of‐Life Outcomes in Movement Disorders
Background: Breathing, eating, and talking (BET) impairments are common yet frequently underrecognized features of movement disorders. Deficits in respiration, swallowing, voice, and speech may emerge early in the course of a disease, adversely affecting safety, participation, and quality of life. Routine neurological examinations may not adequately capture their impact. Objective: To characterize the clinical importance of BET dysfunction across several movement disorders by comparing neurological and speech‐language pathology (SLP) approaches to assessment and recommendations for improved early identification, referral and multidisciplinary management. Methods: Case examples were used to illustrate and compare clinical findings obtained through standard neurological evaluation versus comprehensive SLP assessment. A targeted literature review and comparison of commonly used neurology and SLP clinical tools were also conducted to examine current approaches to BET evaluation and referral. Results: Case examples illustrated how routine neurological examinations underestimated the severity and functional impact of BET impairments. This was contrasted with SLP identification of clinically meaningful deficits in respiratory function, cough, swallowing safety, communication effectiveness, and quality of life not captured by standard disease rating scales. Review of the literature demonstrated that commonly used neurological rating scales provide limited evaluation of BET dysfunction, whereas multidisciplinary assessment incorporating caregiver input, patient‐reported outcomes, perceptual evaluation, and instrumental testing improves detection and treatment planning. Conclusion: BET dysfunction is prevalent across movement disorders and substantially influences quality of life. Early referral to SLPs and integration of multidisciplinary BET assessment can improve diagnostic precision, facilitate timely intervention, reduce preventable complications, and support person‐centered care throughout disease progression.
- 6 July 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 150, 108409
A sacred prelude to aphasia: Demystifying a diagnostic trinity
- 6 July 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 150, 108409
A sacred prelude to aphasia: Demystifying a diagnostic trinity
- 24 March 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (7) , 1727-1739
Risk Factors for the Diagnosis of Progressive Supranuclear Palsy in the UK Biobank
Background: Progressive supranuclear palsy (PSP) is a tauopathy for which there is limited understanding of epidemiological risk factors. Objective: The objective of this study was to identify premorbid nonmedical and medical risk factors for PSP diagnosis in a large prospective population‐based cohort. Methods: We performed a matched nested case–control study using the UK Biobank (UKB) cohort consisting of >500,000 adults aged 37 to 73 years. PSP diagnoses were identified from 2007 to censor date (August 2025) and matched 1:10 by age and sex to control subjects without parkinsonism or dementia diagnoses. We derived risk factors using an iterative logistic regression approach. Results: There were 240 incident PSP diagnoses in the UKB. In the fully adjusted model, premorbid depression (odds ratio [OR], 3.22; 95% confidence interval [CI], 2.30–4.50; P < 0.001), delirium (OR, 6.76; 95% CI, 4.08–11.19; P < 0.001), and functional gastrointestinal disorders (OR, 1.91; 95% CI, 1.39–2.63; P < 0.001) were associated with increased risk. Heavy alcohol consumption was associated with higher risk compared with moderate consumption (OR, 1.65; 95% CI: 1.21–2.26; P = 0.0017). Body mass index (BMI) and alcohol consumption had nonlinear risk profiles. Cancer diagnosis was inversely associated with PSP (OR, 0.56; 95% CI, 0.40–0.79; P < 0.001). Depression and delirium diagnoses remained significant 5 to 10 years before diagnosis. Conclusions: In this large prospective cohort, PSP was associated with premorbid lifestyle practices and neuropsychiatric diagnoses years before diagnosis. This suggests a long premotor phase and highlights opportunities for earlier diagnosis and further mechanistic investigation. The inverse association with cancer mirrors the relationship seen in other neurodegenerative conditions and may point toward shared mechanisms. © 2026 International Parkinson and Movement Disorder Society.
- 24 March 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (7) , 1727-1739
Risk Factors for the Diagnosis of Progressive Supranuclear Palsy in the UK Biobank
Background: Progressive supranuclear palsy (PSP) is a tauopathy for which there is limited understanding of epidemiological risk factors. Objective: The objective of this study was to identify premorbid nonmedical and medical risk factors for PSP diagnosis in a large prospective population‐based cohort. Methods: We performed a matched nested case–control study using the UK Biobank (UKB) cohort consisting of >500,000 adults aged 37 to 73 years. PSP diagnoses were identified from 2007 to censor date (August 2025) and matched 1:10 by age and sex to control subjects without parkinsonism or dementia diagnoses. We derived risk factors using an iterative logistic regression approach. Results: There were 240 incident PSP diagnoses in the UKB. In the fully adjusted model, premorbid depression (odds ratio [OR], 3.22; 95% confidence interval [CI], 2.30–4.50; P < 0.001), delirium (OR, 6.76; 95% CI, 4.08–11.19; P < 0.001), and functional gastrointestinal disorders (OR, 1.91; 95% CI, 1.39–2.63; P < 0.001) were associated with increased risk. Heavy alcohol consumption was associated with higher risk compared with moderate consumption (OR, 1.65; 95% CI: 1.21–2.26; P = 0.0017). Body mass index (BMI) and alcohol consumption had nonlinear risk profiles. Cancer diagnosis was inversely associated with PSP (OR, 0.56; 95% CI, 0.40–0.79; P < 0.001). Depression and delirium diagnoses remained significant 5 to 10 years before diagnosis. Conclusions: In this large prospective cohort, PSP was associated with premorbid lifestyle practices and neuropsychiatric diagnoses years before diagnosis. This suggests a long premotor phase and highlights opportunities for earlier diagnosis and further mechanistic investigation. The inverse association with cancer mirrors the relationship seen in other neurodegenerative conditions and may point toward shared mechanisms. © 2026 International Parkinson and Movement Disorder Society.
- Open Access
- 10 January 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1848-1860
Voice and Speech in Atypical Parkinsonian Disorders
Background: Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics. Objectives: This review aims to characterize speech impairment in APDs, offer practical guidance for clinical evaluation, highlight the role of Speech‐Language pathologists (SLPs) in diagnosis and management, and outline current and emerging management strategies. Methods: A narrative review was conducted by the Diagnosis and Treatment Working Group of CurePSP's Centers of Care, integrating literature and clinical experience to summarize evaluation, diagnosis, and treatment of motor speech disorders in APDs. Results: Speech changes in APDs are often mixed dysarthrias with hypokinetic, spastic, and/or ataxic components, and may include apraxia of speech; these are frequently more severe and progress quicker than in Parkinson's disease. These features can assist in differential diagnosis and should prompt early referral to SLPs. Despite the high prevalence of speech and voice changes, comprehensive assessment of motor speech disorders is uncommon in neurology clinics. Current evidence regarding the efficacy of interventions is mixed. Digital acoustic analysis and neuromodulation offer promising directions for diagnosis and treatment. Conclusions: Early, collaborative management of motor speech impairment elevates care in APDs. Neurologists and SLPs must work together to improve recognition, diagnosis, and care. Future research should focus on objective biomarkers and personalized therapies to support communication, autonomy, and quality of life for individuals living with APDs.
- 10 January 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1848-1860
Open AccessVoice and Speech in Atypical Parkinsonian Disorders
Background: Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics. Objectives: This review aims to characterize speech impairment in APDs, offer practical guidance for clinical evaluation, highlight the role of Speech‐Language pathologists (SLPs) in diagnosis and management, and outline current and emerging management strategies. Methods: A narrative review was conducted by the Diagnosis and Treatment Working Group of CurePSP's Centers of Care, integrating literature and clinical experience to summarize evaluation, diagnosis, and treatment of motor speech disorders in APDs. Results: Speech changes in APDs are often mixed dysarthrias with hypokinetic, spastic, and/or ataxic components, and may include apraxia of speech; these are frequently more severe and progress quicker than in Parkinson's disease. These features can assist in differential diagnosis and should prompt early referral to SLPs. Despite the high prevalence of speech and voice changes, comprehensive assessment of motor speech disorders is uncommon in neurology clinics. Current evidence regarding the efficacy of interventions is mixed. Digital acoustic analysis and neuromodulation offer promising directions for diagnosis and treatment. Conclusions: Early, collaborative management of motor speech impairment elevates care in APDs. Neurologists and SLPs must work together to improve recognition, diagnosis, and care. Future research should focus on objective biomarkers and personalized therapies to support communication, autonomy, and quality of life for individuals living with APDs.
- Open Access
- 7 January 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (6) , 1522-1527
Patient‐Reported Communication Decline Following Deep Brain Stimulation in Parkinson's Disease
Background: Objective decline in communication abilities following Deep Brain Stimulation (DBS) in People with Parkinson's disease (PwP) is common; however, patient perspectives remain under‐investigated. Objectives: This study examined subjective change in communicative efficacy using the Communicative Participation Item Bank (CPIB) in PwP following DBS. Methods: This study examined change in CPIB in 30 PwP following subthalamic DBS using t ‐tests and examined correlates with cognition. Results: Statistically significant declines in subjective communication efficacy were reported following DBS, t (29) = −3.19, P = 0.003. CPIB decline was not associated with baseline or change in objective language performance after DBS. CPIB decline was not related to laterality of DBS target or pre‐DBS cognitive status. Conclusions: Subjective communication decline is common in PwP who undergo STN‐DBS, but was not associated with objective measures of language and cognition. Findings support incorporating patient‐reported outcomes (eg, CPIB) into DBS evaluations to inform intervention and clarify risk factors for communication decline.
- 7 January 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (6) , 1522-1527
Open AccessPatient‐Reported Communication Decline Following Deep Brain Stimulation in Parkinson's Disease
Background: Objective decline in communication abilities following Deep Brain Stimulation (DBS) in People with Parkinson's disease (PwP) is common; however, patient perspectives remain under‐investigated. Objectives: This study examined subjective change in communicative efficacy using the Communicative Participation Item Bank (CPIB) in PwP following DBS. Methods: This study examined change in CPIB in 30 PwP following subthalamic DBS using t ‐tests and examined correlates with cognition. Results: Statistically significant declines in subjective communication efficacy were reported following DBS, t (29) = −3.19, P = 0.003. CPIB decline was not associated with baseline or change in objective language performance after DBS. CPIB decline was not related to laterality of DBS target or pre‐DBS cognitive status. Conclusions: Subjective communication decline is common in PwP who undergo STN‐DBS, but was not associated with objective measures of language and cognition. Findings support incorporating patient‐reported outcomes (eg, CPIB) into DBS evaluations to inform intervention and clarify risk factors for communication decline.
- Open Access
- 11 July 2025
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 11 (3) , e70134
A common outcome set for trials in dementia with Lewy bodies (DLB COS)
INTRODUCTION: Methodological heterogeneity in dementia with Lewy bodies (DLB) trials contributes to publication bias and makes evidence synthesis and meta‐analysis challenging. We aimed to develop a core outcome set for DLB (DLB COS) trials to improve consistency and comparability in DLB research. METHODS: We conducted a systematic review to identify outcomes and administered a two‐stage Delphi survey to a diverse panel of lay and professional stakeholders. We asked respondents which outcomes should be prioritized and included in DLB COS. RESULTS: Forty‐nine outcomes were presented to survey respondents. Consensus was reached regarding eight outcomes for the final DLB COS: delusions/paranoia; fluctuations in cognition, attention, and arousal; functioning; global cognition; hallucinations; quality of life; motor parkinsonism; and rapid eye movement sleep behavior disorder. DISCUSSION: If adopted, DLB COS can enhance the comparability of research findings and facilitate standardization and harmonization. Highlights: A systematic review revealed heterogeneity in dementia with Lewy bodies (DLB) study outcomes. Our study produced a DLB Core Outcome Set (DLB COS) comprising eight outcomes. DLB COS sets the minimum reporting standards for future trials. DLB‐specific rating scales incorporating these outcomes are needed. Addressing this gap is a strategic priority in DLB research.
- 11 July 2025
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 11 (3) , e70134
Open AccessA common outcome set for trials in dementia with Lewy bodies (DLB COS)
INTRODUCTION: Methodological heterogeneity in dementia with Lewy bodies (DLB) trials contributes to publication bias and makes evidence synthesis and meta‐analysis challenging. We aimed to develop a core outcome set for DLB (DLB COS) trials to improve consistency and comparability in DLB research. METHODS: We conducted a systematic review to identify outcomes and administered a two‐stage Delphi survey to a diverse panel of lay and professional stakeholders. We asked respondents which outcomes should be prioritized and included in DLB COS. RESULTS: Forty‐nine outcomes were presented to survey respondents. Consensus was reached regarding eight outcomes for the final DLB COS: delusions/paranoia; fluctuations in cognition, attention, and arousal; functioning; global cognition; hallucinations; quality of life; motor parkinsonism; and rapid eye movement sleep behavior disorder. DISCUSSION: If adopted, DLB COS can enhance the comparability of research findings and facilitate standardization and harmonization. Highlights: A systematic review revealed heterogeneity in dementia with Lewy bodies (DLB) study outcomes. Our study produced a DLB Core Outcome Set (DLB COS) comprising eight outcomes. DLB COS sets the minimum reporting standards for future trials. DLB‐specific rating scales incorporating these outcomes are needed. Addressing this gap is a strategic priority in DLB research.
- Open Access
- 28 June 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (12) , 2106-2110
Discontinuation of the Clozapine Risk Evaluation and Mitigation Strategy and Implications in Movement Disorders
- 28 June 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (12) , 2106-2110
Open AccessDiscontinuation of the Clozapine Risk Evaluation and Mitigation Strategy and Implications in Movement Disorders
- Open Access
- 1 December 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (6) , e200345
A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders
The most common four neurodegenerative atypical parkinsonian disorders (APDs) are progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB). Their formal diagnostic criteria often require subspecialty experience to implement as designed and all require excluding competing diagnoses without clearly specifying how to do that. Validated diagnostic criteria are not available at all for many of the other common APDs, including normal pressure hydrocephalus (NPH), vascular parkinsonism (VP), or drug-induced parkinsonism (DIP). APDs also include conditions of structural, genetic, vascular, toxic/metabolic, infectious, and autoimmune origin. Their differential diagnosis can be challenging early in the course, if the presentation is atypical, or if a rare or non-neurodegenerative condition is present. This review equips community general neurologists to make an early provisional diagnosis before, or in place of, referral to a tertiary center. Early diagnosis would allay diagnostic uncertainty, allow prompt symptomatic management, provide disease-specific information and support resources, avoid further pointless testing and treatments, and create the possibility of trial referral. We address 64 APDs using one over-arching flow diagram and a series of detailed tables. Most instances of APDs can be diagnosed with a careful history and neurological exam, along with a non-contrast brain MRI. Additional diagnostic tests are rarely needed but are delineated where applicable. Our diagnostic algorithm encourages referral to a tertiary center whenever the general neurologist feels it would be in the patient's best interest. Our algorithm emphasizes that the diagnosis of APDs is an iterative process, refined with the appearance of new diagnostic features, availability of new technology, and advances in scientific understanding of the disorders. Clinicians' proposals for all diagnostic tests for the APDs, including repeat visits, should be discussed with patients and their families to ensure that the potential information to be gained aligns with their larger clinical goals. We designed this differential diagnostic algorithm for the APDs to enhance general neurologists' diagnostic skills and confidence and to help them address the less common or more ambiguous cases.
- 1 December 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (6) , e200345
Open AccessA General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders
The most common four neurodegenerative atypical parkinsonian disorders (APDs) are progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB). Their formal diagnostic criteria often require subspecialty experience to implement as designed and all require excluding competing diagnoses without clearly specifying how to do that. Validated diagnostic criteria are not available at all for many of the other common APDs, including normal pressure hydrocephalus (NPH), vascular parkinsonism (VP), or drug-induced parkinsonism (DIP). APDs also include conditions of structural, genetic, vascular, toxic/metabolic, infectious, and autoimmune origin. Their differential diagnosis can be challenging early in the course, if the presentation is atypical, or if a rare or non-neurodegenerative condition is present. This review equips community general neurologists to make an early provisional diagnosis before, or in place of, referral to a tertiary center. Early diagnosis would allay diagnostic uncertainty, allow prompt symptomatic management, provide disease-specific information and support resources, avoid further pointless testing and treatments, and create the possibility of trial referral. We address 64 APDs using one over-arching flow diagram and a series of detailed tables. Most instances of APDs can be diagnosed with a careful history and neurological exam, along with a non-contrast brain MRI. Additional diagnostic tests are rarely needed but are delineated where applicable. Our diagnostic algorithm encourages referral to a tertiary center whenever the general neurologist feels it would be in the patient's best interest. Our algorithm emphasizes that the diagnosis of APDs is an iterative process, refined with the appearance of new diagnostic features, availability of new technology, and advances in scientific understanding of the disorders. Clinicians' proposals for all diagnostic tests for the APDs, including repeat visits, should be discussed with patients and their families to ensure that the potential information to be gained aligns with their larger clinical goals. We designed this differential diagnostic algorithm for the APDs to enhance general neurologists' diagnostic skills and confidence and to help them address the less common or more ambiguous cases.